Dr Reddys ropes in Penny Wan as Additional Director

Prior to Amgen, Wan was General Manager of Roche Pharma China, which became one of the fastest growing multinational corporations in the Country. She spearheaded innovative partnership solutions with government, professional and patient groups to improve access and outcomes for patients. Wan also worked in the pharmaceuticals division of Wyeth, where she held various management, marketing and commercial positions in the US, Hong Kong, and Taiwan.

During her time in China, Wan served as an executive committee member of DPAC (R&D based Pharmaceutical Association Committee), where she led the industry-shaping efforts in biologics and served as Vice President of the Shanghai Association of Enterprises with Foreign Investments. She received the 2013 White Magnolia Memorial Award from the Shanghai municipality in recognition of her contributions to the city.

Penny brings deep experience across healthcare. She has comprehensive management experience and strategic skills in leading sales and marketing, manufacturing, business development, start-up, country and regional operations in global markets, including China and Japan in world class pharma and healthcare companies.

Penny is a confident, articulate executive with a strong presence. She has been a hands-on executive and attributes her success to understanding science, handpicking the team, resource allocation and savvy business judgments. Additionally, Penny has worked across multiple sectors in pharma, infant formula, nutrition, vaccines, immunology, oncology, cardiovascular, bone and mental health, etc.

Penny holds a Graduate Diploma in business administration from Monash University & Chinese University of Hong Kong and a Bachelor of Science in Biochemistry and Pharmacology from Monash University of Australia.

Read also: Ex-Sanofi MD Rajaram Narayanan appointed as SeQuent Scientific MD, CEO